Stay updated on Pembrolizumab Combo in ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in ES-SCLC Clinical Trial page
- CheckyesterdayChange DetectedThe page now shows Revision: v3.6.6, replacing the previous v3.6.5. This indicates a maintenance/update to the page's underlying system rather than changes to the study content.SummaryDifference0.0%

- Check8 days agoChange DetectedA 2023 U.S. NIH Grant/Contract funding line was added to the study's funding disclosures, updating the source of support for the trial.SummaryDifference0.0%

- Check15 days agoChange DetectedTumor size change definitions were added to specify that change is the best percent change from baseline in the sum of target lesions, assessed by centralized review (BICR) per RECIST 1.1, and the mean of this metric is presented. The EORTC QLQ-C30 quality-of-life description was expanded to explain scoring and interpretation (7-point scale and 0–100 normalization), and the Plain Language Summary was removed.SummaryDifference0.3%

- Check22 days agoChange DetectedThe page's revision stamp changed from v3.6.4 to v3.6.5, indicating a newer build of the page. This update reflects an internal release/version update rather than content changes.SummaryDifference0.0%

- Check36 days agoChange DetectedRevision: v3.6.4 is now shown on the page, replacing Revision: v3.6.3. This indicates a new build/version update and does not alter study details, data, or visible layout.SummaryDifference0.0%

- Check58 days agoChange DetectedResults have been posted for NCT04924101 on 2026-07-01, with the page listing primary and secondary outcomes and related QoL and safety data per RECIST 1.1. The update also references the study protocol and statistical plan documents.SummaryDifference1%

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.